electroCore Expands Intellectual Patent Portfolio for nVNS Technology
April 12 2023 - 7:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced that it has received
patent issue notifications from the United States Patent and
Trademark Office (USPTO). The three patents were issued on April
11, 2023, and relate to the electroCore’s non-invasive vagus nerve
stimulation (nVNS) technology, including the following patents:
- US Patent Nos. 11,623,079 and
11,623,080 entitled “Vagal Nerve Stimulation Devices and Methods
for Treating Medical Conditions” and “Vagal Nerve Stimulation for
Dopamine-Related Conditions,” respectively. These patents generally
relate to nVNS devices and methods for treating addiction and other
medical conditions by releasing dopamine and/or endogenous opioids
in the patient's brain.
- US Patent No. 11,623,078 entitled
“Devices and Methods for Non-Invasive Vagal Nerve Stimulation.”
This patent generally relates to devices and methods for modulating
the vagus nerve by transmitting an electrical impulse
transcutaneously through the neck of a patient, wherein the
electrical impulse comprises bursts of 2 to 20 pulses having a
frequency of about 10 to 35 Hz.
“electroCore continues to broaden its intellectual property
portfolio, which consists of over 200 patents and patent
applications,” stated Dan Goldberger, Chief Executive Officer of
electroCore. “We are focused on exploring ways in which nVNS can
help treat a variety of disorders, such as addiction or other
dopamine-related conditions, aside from our FDA-cleared use for
primary headache.”
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans; its pipeline or potential markets for
its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the issuance of U.S. and
international patents providing expanded IP coverage; the
possibility of future business models, the potential of nVNS
generally and gammaCore in particular and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to obtain
additional financing necessary to continue electroCore's business,
sales and marketing and product development plans, the
uncertainties inherent in the development of new products or
technologies, the ability to successfully commercialize gammaCore™,
competition in the industry in which electroCore operates and
general market conditions. All forward-looking statements are made
as of the date of this press release, and electroCore undertakes no
obligation to update forward-looking statements or to update the
reasons why actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should refer to all information set forth in this document and
should also refer to the disclosure of risk factors set forth in
the reports and other documents electroCore files with the SEC,
available at www.sec.gov.
Contact:Rich CockrellCG
Capital404-736-3838ecor@cg.capital
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2024 to Jul 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Jul 2023 to Jul 2024